{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:04:38Z","timestamp":1778227478110,"version":"3.51.4"},"reference-count":34,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>It is unclear whether HER2+ tumors expressing both estrogen receptor (ER) and progesterone receptor (PR), that is, triple-positive breast carcinomas (TPBCs), show unique morphologic and clinical features and response to neoadjuvant chemotherapy (NAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To study the morphologic and immunohistochemical features of TPBCs from patients who underwent NAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We retrospectively reviewed core biopsy and post-NAC slides of 85 TPBCs. H-scores were calculated for ER and PR. HER2 slides and fluorescence in situ hybridization (FISH) reports were reviewed. Residual cancer burden was calculated for post-NAC specimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Eighty-one of the 85 tumors (95.3%) showed ductal histology, 3 (3.5%) were invasive lobular carcinomas, and 1 (1.2%) showed mixed ductal and lobular features. A subset showed mucinous (n = 7, 8.2%), apocrine (n = 5, 5.9%), and\/or micropapillary (n = 4, 4.7%) differentiation. Fifty-four TPBCs (63.5%) showed high ER expression (H-score &amp;gt;200), including 27 (31.8%) with high expression of ER and PR. Fifty-two tumors (61.1%) showed HER2 3+ staining. Mean HER2\/CEP17 ratio by FISH was 3.6 (range, 2\u201312.2) and mean HER2 signals per cell was 8 (range, 3.7\u201330.4). Pathologic complete response (pCR) rate was 35.3% (30 of 85). HER2 3+ staining was the only significant predictor of pCR on multivariate analysis (odds ratio = 9.215; 95% CI, 2.401\u201335.371; P &amp;lt; .001). The ER\/PR expression did not correlate with response to therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>TPBCs are heterogeneous with some showing mucinous, lobular, or micropapillary differentiation. The pCR rate of TPBCs is similar to that reported for ER+\/PR\u2212\/HER2+ tumors. HER2 overexpression by IHC was associated with significantly better response to therapy and may help select patients for treatment in the neoadjuvant setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2020-0293-oa","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T13:11:57Z","timestamp":1603890717000},"page":"728-735","source":"Crossref","is-referenced-by-count":11,"title":["Triple-Positive Breast Carcinoma: Histopathologic Features and Response to Neoadjuvant Chemotherapy"],"prefix":"10.5858","volume":"145","author":[{"given":"Jennifer","family":"Zeng","sequence":"first","affiliation":[{"name":"From the Departments of Pathology (Zeng, Edelweiss, Ross, Xu, Brogi, D'Alfonso), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"Edelweiss","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Zeng, Edelweiss, Ross, Xu, Brogi, D'Alfonso), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dara S.","family":"Ross","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Zeng, Edelweiss, Ross, Xu, Brogi, D'Alfonso), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Zeng, Edelweiss, Ross, Xu, Brogi, D'Alfonso), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy-Ann","family":"Moo","sequence":"additional","affiliation":[{"name":"Breast Surgical Oncology (Moo), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Zeng, Edelweiss, Ross, Xu, Brogi, D'Alfonso), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy M.","family":"D'Alfonso","sequence":"additional","affiliation":[{"name":"From the Departments of Pathology (Zeng, Edelweiss, Ross, Xu, Brogi, D'Alfonso), Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"key":"2021052618104425000_i1543-2165-145-6-728-b01","doi-asserted-by":"crossref","unstructured":"Slamon\n              DJ,\n            \n            \n              Clark\n              GM,\n            \n            \n              Wong\n              SG,\n            \n            et al.\n          \n          Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene.\n\t\t\t\t\tScience.\n\t\t\t\t\t1987;\n\t\t\t\t\t235(4785):\n\t\t\t\t\t177\u2013\n\t\t\t\t\t182.","DOI":"10.1126\/science.3798106"},{"key":"2021052618104425000_i1543-2165-145-6-728-b02","doi-asserted-by":"crossref","unstructured":"Kallioniemi\n              OP,\n            \n            \n              Holli\n              K,\n            \n            \n              Visakorpi\n              T,\n            \n            et al.\n          \n          Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer.\n\t\t\t\t\tInt J Cancer.\n\t\t\t\t\t1991;\n\t\t\t\t\t49(5):\n\t\t\t\t\t650\u2013\n\t\t\t\t\t655.","DOI":"10.1002\/ijc.2910490504"},{"key":"2021052618104425000_i1543-2165-145-6-728-b03","doi-asserted-by":"crossref","unstructured":"Slamon\n              DJ,\n            \n            \n              Leyland-Jones\n              B,\n            \n            \n              Shak\n              S,\n            \n            et al.\n          \n          Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2001;\n\t\t\t\t\t344(11):\n\t\t\t\t\t783\u2013\n\t\t\t\t\t792.","DOI":"10.1056\/NEJM200103153441101"},{"key":"2021052618104425000_i1543-2165-145-6-728-b04","doi-asserted-by":"crossref","unstructured":"Pegram\n              MD.\n            \n          \n          Treating the HER2 pathway in early and advanced breast cancer.\n\t\t\t\t\tHematol Oncol Clin North Am.\n\t\t\t\t\t2013;\n\t\t\t\t\t27(4):\n\t\t\t\t\t751\u2013\n\t\t\t\t\t765,\n\t\t\t\t\tviii.","DOI":"10.1016\/j.hoc.2013.05.007"},{"key":"2021052618104425000_i1543-2165-145-6-728-b05","doi-asserted-by":"crossref","unstructured":"Cortazar\n              P,\n            \n            \n              Zhang\n              L,\n            \n            \n              Untch\n              M,\n            \n            et al.\n          \n          Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2014;\n\t\t\t\t\t384(9938):\n\t\t\t\t\t164\u2013\n\t\t\t\t\t172.","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"2021052618104425000_i1543-2165-145-6-728-b06","doi-asserted-by":"crossref","unstructured":"Gianni\n              L,\n            \n            \n              Pienkowski\n              T,\n            \n            \n              Im\n              YH,\n            \n            et al.\n          \n          5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2016;\n\t\t\t\t\t17(6):\n\t\t\t\t\t791\u2013\n\t\t\t\t\t800.","DOI":"10.1016\/S1470-2045(16)00163-7"},{"key":"2021052618104425000_i1543-2165-145-6-728-b07","doi-asserted-by":"crossref","unstructured":"Lal\n              P,\n            \n            \n              Tan\n              LK,\n            \n            \n              Chen\n              B.\n            \n          \n          Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.\n\t\t\t\t\tAm J Clin Pathol.\n\t\t\t\t\t2005;\n\t\t\t\t\t123(4):\n\t\t\t\t\t541\u2013\n\t\t\t\t\t546.","DOI":"10.1309\/YMJ3A83TB39MRUT9"},{"key":"2021052618104425000_i1543-2165-145-6-728-b08","doi-asserted-by":"crossref","unstructured":"Baselga\n              J,\n            \n            \n              Bradbury\n              I,\n            \n            \n              Eidtmann\n              H,\n            \n            et al.\n          \n          Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2012;\n\t\t\t\t\t379(9816):\n\t\t\t\t\t633\u2013\n\t\t\t\t\t640.","DOI":"10.1016\/j.yonc.2012.08.022"},{"key":"2021052618104425000_i1543-2165-145-6-728-b09","doi-asserted-by":"crossref","unstructured":"Gianni\n              L,\n            \n            \n              Pienkowski\n              T,\n            \n            \n              Im\n              YH,\n            \n            et al.\n          \n          Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2012;\n\t\t\t\t\t13(1):\n\t\t\t\t\t25\u2013\n\t\t\t\t\t32.","DOI":"10.1016\/S1470-2045(11)70336-9"},{"key":"2021052618104425000_i1543-2165-145-6-728-b10","doi-asserted-by":"crossref","unstructured":"Vici\n              P,\n            \n            \n              Pizzuti\n              L,\n            \n            \n              Sperduti\n              I,\n            \n            et al.\n          \n          \u201cTriple positive\u201d early breast cancer: an observational multicenter retrospective analysis of outcome.\n\t\t\t\t\tOncotarget.\n\t\t\t\t\t2016;\n\t\t\t\t\t7(14):\n\t\t\t\t\t17932\u2013\n\t\t\t\t\t17944.","DOI":"10.18632\/oncotarget.7480"},{"key":"2021052618104425000_i1543-2165-145-6-728-b11","doi-asserted-by":"crossref","unstructured":"Vici\n              P,\n            \n            \n              Pizzuti\n              L,\n            \n            \n              Natoli\n              C,\n            \n            et al.\n          \n          Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis: the RETROHER study.\n\t\t\t\t\tBreast Cancer Res Treat.\n\t\t\t\t\t2014;\n\t\t\t\t\t147(3):\n\t\t\t\t\t599\u2013\n\t\t\t\t\t607.","DOI":"10.1007\/s10549-014-3133-1"},{"key":"2021052618104425000_i1543-2165-145-6-728-b12","doi-asserted-by":"crossref","unstructured":"You\n              SH,\n            \n            \n              Chae\n              BJ,\n            \n            \n              Eom\n              YH,\n            \n            et al.\n          \n          Clinical differences in triple-positive operable breast cancer subtypes in Korean patients: an analysis of Korean Breast Cancer Registry data.\n\t\t\t\t\tJ Breast Cancer.\n\t\t\t\t\t2018;\n\t\t\t\t\t21(4):\n\t\t\t\t\t415\u2013\n\t\t\t\t\t424.","DOI":"10.4048\/jbc.2018.21.e53"},{"key":"2021052618104425000_i1543-2165-145-6-728-b13","doi-asserted-by":"crossref","unstructured":"Hammond\n              ME,\n            \n            \n              Hayes\n              DF,\n            \n            \n              Dowsett\n              M,\n            \n            et al.\n          \n          American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2010;\n\t\t\t\t\t134(6):\n\t\t\t\t\t907\u2013\n\t\t\t\t\t922.","DOI":"10.1200\/JOP.777003"},{"key":"2021052618104425000_i1543-2165-145-6-728-b14","doi-asserted-by":"crossref","unstructured":"Wolff\n              AC,\n            \n            \n              Hammond\n              ME,\n            \n            \n              Hicks\n              DG,\n            \n            et al.\n          \n          Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2014;\n\t\t\t\t\t138(2):\n\t\t\t\t\t241\u2013\n\t\t\t\t\t256.","DOI":"10.5858\/arpa.2013-0953-SA"},{"key":"2021052618104425000_i1543-2165-145-6-728-b15","doi-asserted-by":"crossref","unstructured":"Wolff\n              AC,\n            \n            \n              Hammond\n              MEH,\n            \n            \n              Allison\n              KH,\n            \n            et al.\n          \n          Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t2018;\n\t\t\t\t\t142(11):\n\t\t\t\t\t1364\u2013\n\t\t\t\t\t1382.","DOI":"10.5858\/arpa.2018-0902-SA"},{"key":"2021052618104425000_i1543-2165-145-6-728-b16","unstructured":"McCarty\n              KS\n              Jr,\n            \n            \n              Miller\n              LS,\n            \n            \n              Cox\n              EB,\n            \n            et al.\n          \n          Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.\n\t\t\t\t\tArch Pathol Lab Med.\n\t\t\t\t\t1985;\n\t\t\t\t\t109(8):\n\t\t\t\t\t716\u2013\n\t\t\t\t\t721."},{"key":"2021052618104425000_i1543-2165-145-6-728-b17","doi-asserted-by":"crossref","unstructured":"Landmann\n              A,\n            \n            \n              Farrugia\n              DJ,\n            \n            \n              Zhu\n              L,\n            \n            et al.\n          \n          Low estrogen receptor (ER)-positive breast cancer and neoadjuvant systemic chemotherapy: is response similar to typical ER-positive or ER-negative disease?\n          \n            Am J Clin Pathol\n          .\n\t\t\t\t\t2018;\n\t\t\t\t\t150(1):\n\t\t\t\t\t34\u2013\n\t\t\t\t\t42.","DOI":"10.1093\/ajcp\/aqy028"},{"key":"2021052618104425000_i1543-2165-145-6-728-b18","doi-asserted-by":"crossref","unstructured":"Symmans\n              WF,\n            \n            \n              Peintinger\n              F,\n            \n            \n              Hatzis\n              C,\n            \n            et al.\n          \n          Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2007;\n\t\t\t\t\t25(28):\n\t\t\t\t\t4414\u2013\n\t\t\t\t\t4422.","DOI":"10.1200\/JCO.2007.10.6823"},{"key":"2021052618104425000_i1543-2165-145-6-728-b19","doi-asserted-by":"crossref","unstructured":"Stewart\n              RL,\n            \n            \n              Caron\n              JE,\n            \n            \n              Gulbahce\n              EH,\n            \n            et al.\n          \n          HER2 immunohistochemical and fluorescence in situ hybridization discordances in invasive breast carcinoma with micropapillary features.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2017;\n\t\t\t\t\t30(11):\n\t\t\t\t\t1561\u2013\n\t\t\t\t\t1566.","DOI":"10.1038\/modpathol.2017.65"},{"key":"2021052618104425000_i1543-2165-145-6-728-b20","doi-asserted-by":"crossref","unstructured":"von Minckwitz\n              G,\n            \n            \n              Untch\n              M,\n            \n            \n              Blohmer\n              JU,\n            \n            et al.\n          \n          Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.\n\t\t\t\t\tJ Clin Oncol.\n\t\t\t\t\t2012;\n\t\t\t\t\t30(15):\n\t\t\t\t\t1796\u2013\n\t\t\t\t\t1804.","DOI":"10.1200\/JCO.2011.38.8595"},{"key":"2021052618104425000_i1543-2165-145-6-728-b21","doi-asserted-by":"crossref","unstructured":"Schneeweiss\n              A,\n            \n            \n              Chia\n              S,\n            \n            \n              Hickish\n              T,\n            \n            et al.\n          \n          Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2013;\n\t\t\t\t\t24(9):\n\t\t\t\t\t2278\u2013\n\t\t\t\t\t2284.","DOI":"10.1093\/annonc\/mdt182"},{"key":"2021052618104425000_i1543-2165-145-6-728-b22","doi-asserted-by":"crossref","unstructured":"Swain\n              SM,\n            \n            \n              Ewer\n              MS,\n            \n            \n              Viale\n              G,\n            \n            et al.\n          \n          Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t29(3):\n\t\t\t\t\t646\u2013\n\t\t\t\t\t653.","DOI":"10.1093\/annonc\/mdx773"},{"key":"2021052618104425000_i1543-2165-145-6-728-b23","doi-asserted-by":"crossref","unstructured":"Krystel-Whittemore\n              M,\n            \n            \n              Xu\n              J,\n            \n            \n              Brogi\n              E,\n            \n            et al.\n          \n          Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy.\n\t\t\t\t\tBreast Cancer Res Treat.\n\t\t\t\t\t2019;\n\t\t\t\t\t177(1):\n\t\t\t\t\t61\u2013\n\t\t\t\t\t66.","DOI":"10.1007\/s10549-019-05295-9"},{"key":"2021052618104425000_i1543-2165-145-6-728-b24","doi-asserted-by":"crossref","unstructured":"Kogawa\n              T,\n            \n            \n              Fouad\n              TM,\n            \n            \n              Liu\n              DD,\n            \n            et al.\n          \n          High HER2\/centromeric probe for chromosome 17 fluorescence in situ hybridization ratio predicts pathologic complete response and survival outcome in patients receiving neoadjuvant systemic therapy with trastuzumab for HER2-overexpressing locally advanced breast cancer.\n\t\t\t\t\tOncologist.\n\t\t\t\t\t2016;\n\t\t\t\t\t21(1):\n\t\t\t\t\t21\u2013\n\t\t\t\t\t27.","DOI":"10.1634\/theoncologist.2015-0101"},{"key":"2021052618104425000_i1543-2165-145-6-728-b25","doi-asserted-by":"crossref","unstructured":"Singer\n              CF,\n            \n            \n              Tan\n              YY,\n            \n            \n              Fitzal\n              F,\n            \n            et al.\n          \n          Pathological complete response to neoadjuvant trastuzumab is dependent on HER2\/CEP17 ratio in HER2-amplified early breast cancer.\n\t\t\t\t\tClin Cancer Res.\n\t\t\t\t\t2017;\n\t\t\t\t\t23(14):\n\t\t\t\t\t3676\u2013\n\t\t\t\t\t3683.","DOI":"10.1158\/1078-0432.CCR-16-2373"},{"key":"2021052618104425000_i1543-2165-145-6-728-b26","doi-asserted-by":"crossref","unstructured":"Fumagalli\n              D,\n            \n            \n              Venet\n              D,\n            \n            \n              Ignatiadis\n              M,\n            \n            et al.\n          \n          RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO Randomized Clinical Trial.\n\t\t\t\t\tJAMA Oncol.\n\t\t\t\t\t2017;\n\t\t\t\t\t3(2):\n\t\t\t\t\t227\u2013\n\t\t\t\t\t234.","DOI":"10.1001\/jamaoncol.2016.3824"},{"key":"2021052618104425000_i1543-2165-145-6-728-b27","doi-asserted-by":"crossref","unstructured":"Ballard\n              M,\n            \n            \n              Jalikis\n              F,\n            \n            \n              Krings\n              G,\n            \n            et al.\n          \n          \u2018Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2017;\n\t\t\t\t\t30(2):\n\t\t\t\t\t227\u2013\n\t\t\t\t\t235.","DOI":"10.1038\/modpathol.2016.175"},{"key":"2021052618104425000_i1543-2165-145-6-728-b28","doi-asserted-by":"crossref","unstructured":"Lee\n              HJ,\n            \n            \n              Park\n              IA,\n            \n            \n              Park\n              SY,\n            \n            et al.\n          \n          Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer.\n\t\t\t\t\tBreast Cancer Res Treat.\n\t\t\t\t\t2014;\n\t\t\t\t\t145(3):\n\t\t\t\t\t615\u2013\n\t\t\t\t\t623.","DOI":"10.1007\/s10549-014-2983-x"},{"key":"2021052618104425000_i1543-2165-145-6-728-b29","doi-asserted-by":"crossref","unstructured":"Bhargava\n              R,\n            \n            \n              Dabbs\n              DJ,\n            \n            \n              Beriwal\n              S,\n            \n            et al.\n          \n          Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.\n\t\t\t\t\tMod Pathol.\n\t\t\t\t\t2011;\n\t\t\t\t\t24(3):\n\t\t\t\t\t367\u2013\n\t\t\t\t\t374.","DOI":"10.1038\/modpathol.2010.209"},{"key":"2021052618104425000_i1543-2165-145-6-728-b30","doi-asserted-by":"crossref","unstructured":"Ranade\n              A,\n            \n            \n              Batra\n              R,\n            \n            \n              Sandhu\n              G,\n            \n            et al.\n          \n          Clinicopathological evaluation of 100 cases of mucinous carcinoma of breast with emphasis on axillary staging and special reference to a micropapillary pattern.\n\t\t\t\t\tJ Clin Pathol.\n\t\t\t\t\t2010;\n\t\t\t\t\t63(12):\n\t\t\t\t\t1043\u2013\n\t\t\t\t\t1047.","DOI":"10.1136\/jcp.2010.082495"},{"key":"2021052618104425000_i1543-2165-145-6-728-b31","doi-asserted-by":"crossref","unstructured":"Kim\n              HJ,\n            \n            \n              Park\n              K,\n            \n            \n              Kim\n              JY,\n            \n            et al.\n          \n          Prognostic significance of a micropapillary pattern in pure mucinous carcinoma of the breast: comparative analysis with micropapillary carcinoma.\n\t\t\t\t\tJ Pathol Transl Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t51(4):\n\t\t\t\t\t403\u2013\n\t\t\t\t\t409.","DOI":"10.4132\/jptm.2017.03.18"},{"key":"2021052618104425000_i1543-2165-145-6-728-b32","doi-asserted-by":"crossref","unstructured":"Barbashina\n              V,\n            \n            \n              Corben\n              AD,\n            \n            \n              Akram\n              M,\n            \n            et al.\n          \n          Mucinous micropapillary carcinoma of the breast: an aggressive counterpart to conventional pure mucinous tumors.\n\t\t\t\t\tHum Pathol.\n\t\t\t\t\t2013;\n\t\t\t\t\t44(8):\n\t\t\t\t\t1577\u2013\n\t\t\t\t\t1585.","DOI":"10.1016\/j.humpath.2013.01.003"},{"key":"2021052618104425000_i1543-2165-145-6-728-b33","doi-asserted-by":"crossref","unstructured":"Pareja\n              F,\n            \n            \n              Selenica\n              P,\n            \n            \n              Brown\n              DN,\n            \n            et al.\n          \n          Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.\n\t\t\t\t\tHistopathology.\n\t\t\t\t\t2019;\n\t\t\t\t\t75(1):\n\t\t\t\t\t139\u2013\n\t\t\t\t\t145.","DOI":"10.1111\/his.13853"},{"key":"2021052618104425000_i1543-2165-145-6-728-b34","doi-asserted-by":"crossref","unstructured":"Al-Baimani\n              K,\n            \n            \n              Bazzarelli\n              A,\n            \n            \n              Clemons\n              M,\n            \n            et al.\n          \n          Invasive pleomorphic lobular carcinoma of the breast: pathologic, clinical, and therapeutic considerations.\n\t\t\t\t\tClin Breast Cancer.\n\t\t\t\t\t2015;\n\t\t\t\t\t15(6):\n\t\t\t\t\t421\u2013\n\t\t\t\t\t425.","DOI":"10.1016\/j.clbc.2015.06.010"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/6\/728\/2835581\/i1543-2165-145-6-728.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/6\/728\/2835581\/i1543-2165-145-6-728.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:41:32Z","timestamp":1764790892000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/6\/article-p728.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,10,28]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2020-0293-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,28]]}}}